Chữ ký PAM50 dựa trên nghiên cứu và khả năng sống sót lâu dài ở bệnh nhân ung thư vú
Tóm tắt
Từ khóa
Tài liệu tham khảo
Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M, Glas AM, d’Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ, Consortium T (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98(17):1183–1192. https://doi.org/10.1093/jnci/djj329
Cardoso F, Piccart-Gebhart M, Van’t Veer L, Rutgers E, Consortium T (2007) The MINDACT trial: the first prospective clinical validation of a genomic tool. Mol Oncol 1(3):246–251. https://doi.org/10.1016/j.molonc.2007.10.004
Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MCU, Mardis ER, Perou CM, Bernard PS, Ellis MJ (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16(21):5222–5232. https://doi.org/10.1158/1078-0432.ccr-10-1282
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826. https://doi.org/10.1056/NEJMoa041588
Prat A, Ellis MJ, Perou CM (2012) Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol 9(1):48–57. https://doi.org/10.1038/nrclinonc.2011.178
Tang G, Shak S, Paik S, Anderson S, Costantino J, Geyer CJ, Mamounas E, Wickerham D, Wolmark N (2011) Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 127(1):133–142. https://doi.org/10.1007/s10549-010-1331-z
van’t Veer LJ, Dai HY, van de Vijver MJ, He YDD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536. https://doi.org/10.1038/415530a
Sestak I, Cuzick J (2015) Markers for the identification of late breast cancer recurrence. Breast Cancer Res 17:10. https://doi.org/10.1186/s13058-015-0516-0
Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo JQ, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA (2011) Randomized Phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 29(17):2342–2349. https://doi.org/10.1200/Jco.2010.31.6950
Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He XP, Hu ZY, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167. https://doi.org/10.1200/jco.2008.18.1370
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. https://doi.org/10.1038/35021093
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98(19):10869–10874. https://doi.org/10.1073/pnas.191367098
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100(14):8418–8423. https://doi.org/10.1073/pnas.0932692100
Buus R, Sestak I, Kronenwett R, Denkert C, Dubsky P, Krappmann K, Scheer M, Petry C, Cuzick J, Dowsett M (2016) Comparison of EndoPredict and EPclin with oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djw149
Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, Ferree S, Sgroi D, Schnabel C, Baehner FL, Mallon E, Dowsett M (2018) Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 4(4):545–553. https://doi.org/10.1001/jamaoncol.2017.5524
Nielsen T, Wallden B, Schaper C, Ferree S, Liu SZ, Gao DX, Barry G, Dowidar N, Maysuria M, Storhoff J (2014) Analytical validation of the PAM50-based prosigna breast cancer prognostic gene signature assay and ncounter analysis system using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer. https://doi.org/10.1186/1471-2407-14-177
Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, Liu SZ, Leung S, Geiss G, Snider J, Vickery T, Davies SR, Mardis ER, Gnant M, Sestak I, Ellis MJ, Perou CM, Bernard PS, Parker JS (2015) Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genom. https://doi.org/10.1186/s12920-015-0129-6
Buffa FM, Harris AL, West CM, Miller CJ (2010) Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 102(2):428–435. https://doi.org/10.1038/sj.bjc.6605450
Hu Z, Fan C, Livasy C, He X, Oh DS, Ewend MG, Carey LA, Subramanian S, West R, Ikpatt F, Olopade OI, van de Rijn M, Perou CM (2009) A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med 7:9. https://doi.org/10.1186/1741-7015-7-9
Tibshirani R (1997) The lasso method for variable selection in the Cox model. Stat Med 16(4):385–395
Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thurlimann B, Gianni L, Castiglione M, Gelber RD, Coates AS, Goldhirsch A (2016) Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol 34(9):927–935. https://doi.org/10.1200/jco.2015.62.3504
Natarajan L, Pu MY, Parker BA, Thomson CA, Caan BJ, Flatt SW, Madlensky L, Hajek RA, Al-Delaimy WK, Saquib N, Gold EB, Pierce JP (2009) Time-varying effects of prognostic factors associated with disease-free survival in breast cancer. Am J Epidemiol 169(12):1463–1470. https://doi.org/10.1093/aje/kwp077
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273–1283. https://doi.org/10.1056/NEJMoa0910383
Bertucci F, Finetti P, Viens P, Birnbaum D (2014) EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. Cancer Lett 355(1):70–75. https://doi.org/10.1016/j.canlet.2014.09.014
Rakha EA, Agarwal D, Green AR, Ashankyty I, Ellis IO, Ball G, Alaskandarany MA (2017) Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer. Histopathology 70(4):622–631. https://doi.org/10.1111/his.13108
Suman VJ, Ellis MJ, Ma CX (2015) The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER +/Her2- invasive breast cancer. Chin Clin Oncol 4(3):34. https://doi.org/10.3978/j.issn.2304-3865.2015.09.01
Zanotti G, Hunger M, Perkins JJ, Horblyuk R, Martin M (2017) Treatment patterns and real world clinical outcomes in ER+/HER2− post-menopausal metastatic breast cancer patients in the United States. Bmc Cancer 17(1):393. https://doi.org/10.1186/s12885-017-3379-1
Pierce JP, Natarajan L, Caan BJ, Parker BA, Greenberg ER, Flatt SW, Rock CL, Kealey S, Al-Delaimy WK, Bardwell WA, Carlson RW, Emond JA, Faerber S, Gold EB, Hajek RA, Hollenbach K, Jones LA, Karanja N, Madlensky L, Marshall J, Newman VA, Ritenbaugh C, Thomson CA, Wasserman L, Stefanick ML (2007) Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer—the Women’s Healthy Eating and Living (WHEL) Randomized Trial. J Am Med Assoc 298(3):289–298. https://doi.org/10.1001/jama298.3.289
Natarajan L, Pu M, Davies SR, Vickery TL, Nelson SH, Pittman E, Parker BA, Ellis MJ, Flatt SW, Mardis ER, Marinac CR, Pierce JP, Messer K (2019) MiRNAs and long-term breast cancer survival: evidence from the WHEL Study. Cancer Epidemiol Biomark Prev. https://doi.org/10.1158/1055-9965.epi-18-1322
Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. https://doi.org/10.1186/bcr2635
Pierce JP, Faerber S, Wright FA, Rock CL, Newman V, Flatt SW, Kealey S, Jones VE, Caan BJ, Gold EB, Haan M, Hollenbach KA, Jones L, Marshall JR, Ritenbaugh C, Stefanick ML, Thomson C, Wasserman L, Natarajan L, Thomas RG, Gilpin EA (2002) A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women’s Healthy Eating and Living (WHEL) Study. Control Clin Trials 23(6):728–756
AJCC (2002) American Joint Committee on Cancer: manual for staging of cancer, 6th edn. Spring-Verlag, New York
Zhao X, Rodland EA, Tibshirani R, Plevritis S (2015) Molecular subtyping for clinically defined breast cancer subgroups. Breast Cancer Res. https://doi.org/10.1186/s13058-015-0520-4
Therneau TM, Grambsch PM (2000) modeling survival data: extending the Cox model. Springer-Verlag, New York
R DCT (2009) The R project for statistical computing (freeware statistics package R)
Sestak I, Buus R, Cuzick J, Dudsky P, Kronenwett R, Ferree S, Sgroi D, Schnabel C, Baehner R, Mallon E, Dowsett M (2016) Comprehensive comparison of prognostic signatures for breast cancer recurrence in TransATAC. In: Paper presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 6–10, 2016